Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Wenzhou Medical University

China · Asia-Pacific

#952World rank of 1,038
25.0ICI scoreout of 100
#152National rank, of 169 in China
#305Regional rank, of 343 in Asia-Pacific
360.5Verified industry works, 2021 to 2025
204Company groups worked with (76 on two or more works)

Wenzhou Medical University is ranked #952 of 1,038. It is held back most by co-creation (5): 360.5 verified industry works against about 1,152 expected for its mix of fields; and by breadth (22): partners concentrated in a few research fields.

Research Collaboration Index 2026: #629 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
5

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 360.5 verified works against about 1,152 expected for its fields (0.31 times the expected rate).

Durability20% of the score
31

How much of its industry work sits in sustained partnerships with the same company group. 14 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
43

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 76 company groups on two or more joint works; 14 sustained partnerships.

Breadth20% of the score
22

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (25.0) is the weighted average of the four percentiles. Rank 952 of 1,038 overall; 152 of 169 in China; 305 of 343 in Asia-Pacific. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

1.4%of its 25,090 research works in 2021 to 2025 were co-authored with a verified company
0.31Industry co-authorship rate: 0.31 times what its mix of research fields would predict (360.5 verified works; about 1,152 expected)
14sustained partnerships: the same company group on five or more joint works in three or more of the five years

In China

152 of 169 ranked universities in China

  1. #150 Hunan Normal University world #939, score 25.7
  2. #151 Army Medical University world #941, score 25.6
  3. #152 Wenzhou Medical University world #952, score 25.0
  4. #153 University of Jinan world #953, score 25.0
  5. #154 Central China Normal University world #966, score 23.9

All ranked universities →   Asia-Pacific: 305 of 343 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Strongest sector positions

#265 of 638Pharmaceuticals and Therapeutics106.5 verified works in the sector
Pharmaceuticals and Therapeutics
106.5#265 of 638
Medical Technology and Digital Health
28#287 of 323
Biotechnology and Advanced Therapies
16.5under 20 works
Artificial Intelligence
8under 20 works
Advanced Materials and Nanotechnology
4under 20 works
Climate, Environment and Sustainability
3under 20 works
Advanced Manufacturing and Industry 4.0
2under 20 works
Batteries and Energy Storage
2under 20 works
Agriculture and Food Technology
1under 20 works
Not in any of the 21 sectors
189counted in the overall index

171.5 of its 360.5 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Wenzhou Medical University co-authored verified work with 204 company groups, consortium papers aside: 76 of them on two or more works, and 14 as sustained partners.

The largest 12 of its 204 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
EchosensFranceMedicine16.53 of 5
Dian DiagnosticsChinaMedicine165 of 5
United Imaging HealthcareChinaMedicine134 of 5
AstraZenecaUnited KingdomMedicine115 of 5
BGI GroupChinaBiochemistry, Genetics and Molecular Biology105 of 5
Jiangsu Hengrui MedicineChinaMedicine105 of 5
MedtronicIrelandMedicine75 of 5
PhilipsNetherlandsEngineering74 of 5
PfizerUnited StatesMedicine64 of 5
3D MedicinesChinaMedicine64 of 5
AbbVieUnited StatesMedicine5.53 of 5

1 further partner group is not named here because the open record gives an address, a person's name or other text in place of an organisation's name; its joint works still count in every figure on this page.

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.

Over time

Verified industry works by year

38.52021
642022
622023
882024
1082025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

10 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07153744 Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction with Shanghai Hutchison Pharmaceuticals Limited, 2025
  • NCT06633042 The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD with Bioray Laboratories, 2024
  • NCT06420154 The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases with Shanghai First Song Therapeutics Co., Ltd, 2024
  • NCT05813704 Coronary Crossing System in Patients With Coronary Chronic Total Occlusions with Shanghai MicroPort Rhythm MedTech Co., Ltd., 2023
  • NCT05824923 A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure with Pulnovo Medical (Wuxi) Co., Ltd., 2023
  • NCT05553626 Safety and Effectiveness of Left Bundle Branch Pacing in Patients With Cardiac Dysfunction and AV Block with Medtronic (Shanghai) Management Co. Ltd., 2022

Evidence checked

492 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 953 of 1,445 candidate links were set aside.

Why links were set aside
  • 395 not an industry organisation
  • 305 company name not written in the author's affiliation
  • 92 refresh_university_not_on_work
  • 53 ordinary-word name without a company suffix
  • 39 part of a university or public institute's own unit
  • 19 a place or common word that failed its stricter rule
  • 50 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where Wenzhou Medical University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Wenzhou Medical University ranks #629 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.